Low dose aspirin use from SQX and risk of ovarian cancer
Principal Investigator
Name
Britton Trabert
Degrees
Ph.D., M.S.
Institution
University of Utah/Huntsman Cancer Institute
Position Title
Ass. Professor
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-431
Initial CDAS Request Approval
Dec 18, 2018
Title
Low dose aspirin use from SQX and risk of ovarian cancer
Summary
Aspirin is widely used for treatment of pain, fever, and inflammation, and may be used regularly for prevention of cardiovascular disease (CVD). Currently, the United States Preventive Services Task Force (USPSTF) recommends daily low-dose aspirin for individuals ages 50-60 with a 10-year risk of CVD of 10% or greater, for whom the benefits of daily aspirin most clearly outweigh potential harms.
A growing body of literature indicates that aspirin may also play a role in cancer prevention. Specifically, there is accumulating evidence from observational studies that aspirin may decrease risk of ovarian cancer. Aspirin is thought to mitigate cancer risk via anti-inflammatory and antiplatelet mechanisms. Notably this association has been specific to daily and/or low dose aspirin use and in most studies, but the data on low dose aspirin and ovarian cancer outcomes are limited. Thus, we propose to utilize the questionnaire data collected during follow-up from PLCO that captured information on low dose aspirin use and use this to evaluate the association with subsequent (post-SQX) ovarian cancer risk.
A growing body of literature indicates that aspirin may also play a role in cancer prevention. Specifically, there is accumulating evidence from observational studies that aspirin may decrease risk of ovarian cancer. Aspirin is thought to mitigate cancer risk via anti-inflammatory and antiplatelet mechanisms. Notably this association has been specific to daily and/or low dose aspirin use and in most studies, but the data on low dose aspirin and ovarian cancer outcomes are limited. Thus, we propose to utilize the questionnaire data collected during follow-up from PLCO that captured information on low dose aspirin use and use this to evaluate the association with subsequent (post-SQX) ovarian cancer risk.
Aims
To evaluate whether low dose aspirin use is associated with subsequent ovarian cancer risk.
Collaborators
Lauren Hurwitz
Paul Pinsky
Neal Freedman
Wen-Yi Huang
Related Publications
-
Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
Hurwitz LM, Pinsky PF, Huang WY, Freedman ND, Trabert B
Gynecol. Oncol. 2020 Sep 10 PUBMED